Get started
Author

Nicolas Duveau

Ileal or Anastomotic Location of Lesions Does Not Impact Rate of Postoperative Recurrence in Crohn’s Disease Patients Classified i2 on the Rutgeerts Score
2016 · P. Bayart, N. Duveau, et al. · Digestive Diseases and Sciences · 48
Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: A GETAID multicentre cohort study
2022 · Mathurin Fumery, Antoine Defrance, et al. · Alimentary Pharmacology & Therapeutics · 39
Long-term Outcome of Risankizumab in Crohn’s Disease: a Real-world GETAID Study
2024 · Mathurin Fumery, Benedicte Caron, et al. · Clinical Gastroenterology and Hepatology · 37
Incidence, prevalence and clinical presentation of inflammatory bowel diseases in Northern France: a 30-year population-based study
2024 · Hélène Sarter, Thibaut Crétin, et al. · The Lancet Regional Health - Europe · 35
The IBD-disk Is a Reliable Tool to Assess the Daily-life Burden of Patients with Inflammatory Bowel Disease
2020 · Sara Tadbiri, Maria Nachury, et al. · Journal of Crohn s and Colitis · 35
PDF
Efficacy and safety of combination targeted therapies in immune-mediated inflammatory disease: the COMBIO study
2022 · Lucas Guillo, Benoit Flachaire, et al. · Digestive and Liver Disease · 34
Ustekinumab Serum Trough Levels May Identify Suboptimal Responders to Ustekinumab in Crohn’s Disease
2019 · Claire Painchart, Séverine Brabant, et al. · Digestive Diseases and Sciences · 32
Patients with Crohnʼs Disease with High Body Mass Index Present More Frequent and Rapid Loss of Response to Infliximab
2017 · Loic Guerbau, Romain Gerard, et al. · Inflammatory Bowel Diseases · 29
Radiological Response Is Associated with Better Outcomes and Should Be Considered a Therapeutic Target in Crohn’s Disease
2019 · Eléonore Hallé, Mustapha Azahaf, et al. · Digestive Diseases and Sciences · 26
Steroid-Free Deep Remission at One Year Does Not Prevent Crohn's Disease Progression: Long-Term Data From the TAILORIX Trial
2021 · David Laharie, Geert D’Haens, et al. · Clinical Gastroenterology and Hepatology · 23
Prevalence and Determinants of Fatigue in Patients with IBD: A Cross-Sectional Survey from the GETAID
2023 · Aurelien Amiot, Sayma Chaibi, et al. · Journal of Crohn s and Colitis · 22
PDF
Adalimumab dose escalation is effective and well tolerated in Crohn’s disease patients with secondary loss of response to adalimumab
2016 · Nicolas Duveau, Maria Nachury, et al. · Digestive and Liver Disease · 19
Listeria Monocytogenes-Associated Spontaneous Bacterial Peritonitis: A Nationwide Study of 208 Consecutive Cases
2024 · Florian Blanchard, Benoît Henry, et al. · The Lancet Infectious Diseases · 14
Obesity in adult patients with inflammatory bowel disease: Clinical features and impact on disability. A cross-sectional survey from the GETAID
2023 · Rose Al Bacha, Yoram Bouhnik, et al. · Digestive and Liver Disease · 10
PDF
Patients’ real-world experience with inflammatory bowel disease: A cross-sectional survey in tertiary care centres from the GETAID group
2020 · Maria Nachury, Yoram Bouhnik, et al. · Digestive and Liver Disease · 8
PDF
Switch acceptance and persistence of adalimumab biosimilars in IBD patients: a prospective observational study
2025 · Gabrielle D’Abbundo, Maria Nachury, et al. · Therapeutic Advances in Gastroenterology · 6
DOP65 Infliximab plus azathioprine and quick steroids discontinuation versus azathioprine plus steroids in patients with acute severe Ulcerative Colitis responding to intravenous steroids: a parallel, open-label randomized controlled trial
2024 · A Amiot, P Seksik, et al. · Journal of Crohn s and Colitis · 6
PDF
P360 Trough levels and antibodies to ustekinumab are not correlated to response to ustekinumab treatment in Crohn's disease patients
2017 · P. Claire, B. Severine, et al. · Journal of Crohn s and Colitis · 6
Incidence and risk factors for thromboembolic events in pediatric-onset inflammatory bowel disease: A French population-based study
2024 · Nicolas Richard, Ariane Leroyer, et al. · Digestive and Liver Disease · 5
Subcutaneous Infliximab for Perianal Crohn's Disease: The BioLap-Rem Multicenter Study From the GETAID
2025 · Marie André, Julien Kirchgesner, et al. · The American Journal of Gastroenterology · 4
Trough Levels and Antibodies to Ustekinumab are not Correlated to Response to Ustekinumab Treatment in Crohn's Disease Patients
2017 · Painchart Claire, Severine Brabant, et al. · Gastroenterology · 3
Subcutaneous vedolizumab dose intensification in inflammatory bowel disease patients: the OPTI-VEDO multicenter study from the GETAID
2025 · Pauline Wils, Romain Altwegg, et al. · Journal of Crohn s and Colitis · 2
P857 Effectiveness and safety of subcutaneous infliximab in perianal Crohn's disease: a multicentre cohort study
2024 · M Andre, J Kirchgesner, et al. · Journal of Crohn s and Colitis · 2
PDF
Sa1960 Crohn's Disease Patients With High Body Mass Index Present More Frequent and Rapid Loss of Response to Infliximab
2016 · Loic Guerbau, Romain Gerard, et al. · Gastroenterology · 2
1176 Effectiveness and Safety of Subcutaneous Infliximab in Perianal Crohn's Disease: a Multicentre Cohort Study
2024 · Marie André, Julien Kirchgesner, et al. · Gastroenterology · 1
Works count: 43
Citation count: 450
H-index: 13
I10-index: 14
Year
Topic
Type